Low AMH and GnRH-antagonist strategies

To the Editor:

We read with interest the case report by Tocci reporting a live birth in a woman with a negligible anti-Mullerian hormone (AMH) as defined by an AMH of <3.5 pmol/L (1).  We have previously reported a prospective cohort of 61 women with a median AMH of 3.0 (IQR 2.0 -3.8) pmol/L, where use of antagonist cycles without preprogramming achieved a clinical pregnancy rate of 14.7% per cycle started and a trend towards higher pregnancy rates as compared to agonist cycles [adjusted OR 2.89 (95% CI 0.88 -9.50); p=0.08](2). 

Comment on “Body mass index is an independent risk factor for the development of endometrial polyps in patients undergoing in vitro fertilization.”

To the Editor:

We would like to make some comments on the paper by Onalan et al (1). In this paper, the authors found that obesity could be a factor in initiating the growth of an endometrial polyp because they identified obesity as the only independent risk factor using logistic regression analysis.

Lack of clinical and scientific evidence to justify the systematic use of ICSI in HIV-serodiscordant couples wishing to conceive where the male partner is infected

 

To the Editor:

 

Sauer et al. (1) reported, in a recent Fertility and Sterility issue, 10 years’ experience of an ICSI program in 181 HIV-serodiscordant couples. One hundred three deliveries were reported. It’s noteworthy that the multiple pregnancy (MP) rate was 41%, and 43% of infants were born preterm. Twenty-one infants weighed less than 1500 grams. No female HIV-seroconversions occurred.